# Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT06028828** · PHASE2 · RECRUITING · sponsor: **University of California, Irvine** · enrollment: 60 (estimated)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Hematologic Malignancies

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **RADIATION:** Total Body Irradiation

## Key facts

- **NCT ID:** NCT06028828
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-11
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06028828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06028828, "Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06028828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*